These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 8957057)

  • 1. Screening for colorectal cancer by immunochemical fecal occult blood testing.
    Saito H
    Jpn J Cancer Res; 1996 Oct; 87(10):1011-24. PubMed ID: 8957057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for colorectal cancer: current status in Japan.
    Saito H
    Dis Colon Rectum; 2000 Oct; 43(10 Suppl):S78-84. PubMed ID: 11052482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test.
    Saito H; Soma Y; Nakajima M; Koeda J; Kawaguchi H; Kakizaki R; Chiba R; Aisawa T; Munakata A
    Oncol Rep; 2000; 7(4):815-9. PubMed ID: 10854550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sensitivity of immunochemical occult blood testing in detecting early colorectal cancer].
    Saito H
    Nihon Rinsho; 1996 May; 54(5):1421-4. PubMed ID: 8965378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Well adjusted qualitative immunochemical faecal occult blood tests could be a promising alternative for inexpensive, high-quality colorectal cancer screening.
    Tao S; Brenner H
    Eur J Cancer Prev; 2013 Jul; 22(4):305-10. PubMed ID: 23702679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study.
    Saito H; Soma Y; Koeda J; Wada T; Kawaguchi H; Sobue T; Aisawa T; Yoshida Y
    Int J Cancer; 1995 May; 61(4):465-9. PubMed ID: 7759151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of fecal occult-blood tests for colorectal-cancer screening.
    Allison JE; Tekawa IS; Ransom LJ; Adrain AL
    N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands.
    Denters MJ; Deutekom M; Fockens P; Bossuyt PM; Dekker E
    BMC Gastroenterol; 2009 Apr; 9():28. PubMed ID: 19393087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.
    Koga Y; Yamazaki N; Yamamoto Y; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1844-52. PubMed ID: 23950216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design.
    Juul JS; Bro F; Hornung N; Andersen BS; Laurberg S; Olesen F; Vedsted P
    BMC Cancer; 2016 Jul; 16():445. PubMed ID: 27400657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal cytology in conjunction with immunofecal occult blood test for colorectal cancer screening.
    Sheng JQ; Li SR; Su H; Li JS; Sun ZQ; Wu ZT; Wu X; Xia CH; Rao J
    Anal Quant Cytol Histol; 2010 Jun; 32(3):131-5. PubMed ID: 20701065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
    Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
    Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for colon cancer: A test for occult blood.
    Khakimov N; Khasanova G; Ershova K; Gibadullina L; Vetkina T; Lobisheva G; Chumakova A
    Int J Risk Saf Med; 2015; 27 Suppl 1():S110-1. PubMed ID: 26639687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients.
    Li S; Wang H; Hu J; Li N; Liu Y; Wu Z; Zheng Y; Wang H; Wu K; Ye H; Rao J
    Int J Cancer; 2006 Jun; 118(12):3078-83. PubMed ID: 16425283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
    Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
    J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.